Presentation on theme: "RESEARCH PROGRAM John W. Mellors, M.D. Professor of Medicine Chief, Division of Infectious Diseases Director, HIV/AIDS Program, UPMC"— Presentation transcript:
RESEARCH PROGRAM John W. Mellors, M.D. Professor of Medicine Chief, Division of Infectious Diseases Director, HIV/AIDS Program, UPMC email@example.com www.pitt.edu/~disease
Basic Research Translational Research Clinical Research Better Treatment and Prevention Understand Drug Resistance Discover New Drugs
Major Projects Discovery of novel nucleoside analogs with activity against drug-resistant HIV New mechanisms of HIV drug resistance Role of low frequency drug-resistant variants in treatment failure Mechanisms of HIV persistence on antiretroviral therapy and strategies for eradication HIV prevention with antiretrovirals
Doctoral Student Training Model Important Clinically Relevant Question? Genetic, Virologic, Biochemical, Structural Studies
C. Shi, PhD 1991- 1997 Development of recombinant retroviral systems for analysis of HIV-1 drug resistance J. Hammond, PhD 1996- 2002 Structural determinants of HIV resistance to nucleoside analogs U. Parikh, PhD 1999- 2005 Antagonistic evolutionary pathways of HIV-1 resistance to NRTI E. Halvas, PhD 2000- Present Role of low frequency drug-resistant variants in antiretroviral treatment failure S. Clark, PhD 2002- Present Genetic, biochemical, and structural mechanisms of NNRTI hypersusceptibility J. Brehm 2005- Present The influence of mutations in the polymerase and RNase H domains on resistance to reverse transcriptase inhibitors J. Meeter 2007- Present Structural basis of nucleoside activity, resistance and toxicity Past/Current Doctoral Trainees
Jessica Brehm Pre-doctoral Student IDM Department - GSPH And member of Mellors Lab since 2004 BS Biochemistry and Chemistry 2003 College of Charleston South Carolina PEER-REVIEWED PUBLICATION 1.Brehm JH, Koontz D, Meteer JD, Pithak V, Sluis-Cremer N, Mellors JW. Selection of Mutations in the Connection and RNase H Domains of Human Immunodeficiency Virus Type 1 Reverse Transcriptase that Increase Resistance to 3'-Azido- 3'-Dideoxythymidine. J Virol 2007;81:7852-9 ABSTRACTS Presented at Conferences 2007-08 1.14th Annual Conference on Retroviruses and Opportunistic Infections (CROI). Feb 2007, Los Angeles, CA. (Oral presentation) 2. XVI International HIV Drug Resistance Workshop June 2007, Barbados. 3.15 th Annual CROI conference, February 2008, Boston, MA (Oral presentation) 4. XVII International HIV Drug Resistance Workshop, June 2008, Sitges, Spain (Oral) Fellowship: Pittsburgh AIDS Research Training Fellow (PART) – 2007-08
Jeff Meteer Pre-doctoral Student Molecular Virology and Microbiology Graduate Program MVM BS Biochemistry 2006 St. John Fisher College, Rochester NY Member of Mellors Lab since 2007 PEER-REVIEWED PUBLICATION Brehm JH, Koontz D, Meteer JD, Pithak V, Sluis-Cremer N, Mellors JW. Selection of Mutations in the connection and RNase H domains of human immunodeficiency virus Type 1 reverse transcriptase that Increase resistance to 3’-azido-3’- Dideoxythymidine. J Virol 2007;81: 7852-9. ABSTRACT Presented at Conference: Meteer J, Koontz D, Rapp KL, Detorio M, Ruckstuhl M, Schinazi RF, Mellors JW. Novel resistance profile of the potent Nucleoside analogue reverse transcriptase Inhibitor 3’-azido-2’,3’-dideoxyguanosine. ORAL PRESENTATION at the XVII International HIV Drug Resistance Workshop. June 2008 Sitges, Spain.
Urvi Parikh, PhD University of Pittsburgh Assistant Professor of Medicine Associate Director Microbial Trials Network Lab Doctoral student in MELLORS LAB 1999-2005 PhD – IDM GSPH 2006 BS Biochemistry and Molecular Biology - 1998 Pennsylvania State University Urvi’s Carrer Path after Mellors Lab….(5 publications, 4 first author) 2006 to 2008 Emerging Infectious Disease Research Fellow Centers for Disease Control and Prevention Laboratory of Walid Heneine, PhD, Division of HIV/AIDS Prevention Laboratory Branch. Conducted in vitro evaluations of nucleoside reverse transcriptase inhibitors for use as a microbicide gel for the prevention of HIV transmission. Also involved In design and implementation of candidate Microbicide safety and efficacy studies in non-human primates. RECRUITED TO PITT FACULTY IN 2008 To serve as Associate Director of Microbial Trials Network and to enhance ID Division global health Initiatives
Nicolas Sluis-Cremer, PhD University of Pittsburgh Assistant Professor Director, Basic Education ID Division
Jessica Radzio Pre-doctoral Student IDM Department of GSPH Sluis-Cremer Lab since 2007 BS Biology - 2001 MS Life Sciences - 2003 Virginia Polytechnic & State University, Blacksburg, VA PEER-REVIEWED PUBLICATIONS 2007-08 1. Radzio J, Sluis-Cremer N. Efavirenz accelerates HIV-1 reverse transcriptase ribonuclease H cleavage, leading to diminished zidovudine excision. Mol Pharmacol 2008;73(2)601-6. 2.Zelina S, Sheen CW, Radzio J, Mellors JW and Sluis-Cremer N. Mechanisms by which the G333D Mutation in human immunodeficiency virus type 1 Reverse transcriptase facilitates dual resistance Protein Sci 2007;16(8) 1728-37. 3.Xia Q, Radzio J and Sluis-Cremer N. Probing Non-nucleoside inhibitor-induced active-site distortion in HIV-1 reverse transcriptase by transient kinetic analyses. Protein Sci 2007(16) (8);1728-37 4. Nissley DV, Radzio J, Anderson KS, Sluis- Cremer N. Characterization of novel non- Nucleoside inhibitor-induced active-site distortion In HIV-1 reverse transcriptase by RT. Biochem J 2007;404(1) 151-7.
Brian Herman Pre-doctoral Student Molecular Virology and Microbiology Graduate Program BS Biology/Biochemistry Allegheny College 2005 Sluis-Cremer Lab 2007 PEER REVIEWED PUBLICATION: Roberts A, Deming D, Paddock CD, Cheng A, Yount B, Vogel L, Herman BD, Sheahan T, Heise M, Genrich GL, Zaki SR, Baric R, Subbarao K. A Mouse-adapted SARS-coronavirus causes disease and mortality in BALB/cmice. PLoS Pathog 2007;3(1):e5 T. PhD Thesis: Structure-activity-resistance Relationships and biochemical Pharmacology of novel nucleoside and Nucleotide HIV-1 reverse transcriptase inhibitors
S. Riddler, MD1991-1994 Antiretroviral activity of stavudine (2’,3’- didehydro’3’-depxythymiding, d4T) H. Nguyen, MD1991-1995 Molecular basis of HIV resistance to NNRTI N. Connolly, MD2002-2005Immune based therapies for HIV infection J. McKinnon, MD2003-2005 Simplified maintenance antiretroviral therapy: Virologic predictors of outcome S. Patel, DO2003-2005 Persistence of multidrug resistant HIV after structured treatment interruptions J. Chow, BS2007-Present Role of minor drug-resistant variants in treatment failure Past MD Fellow Trainees
Laboratory Techniques Experimental design! Cell culture and virology Antiviral susceptibility/cytotoxicity assays −drug assessments Biochemistry of RT and other enzymes Molecular biology −Cloning, PCR, site-specific mutagenesis, DNA sequencing, single genome sequencing Structural biology Application of above to human samples
Expectations Hard work and commitment to science Weekly meetings with supervisor 2 or 3 first author publications (for Ph.D) Scientific presentations at national meetings
Mellors Lab University of Pittsburgh Division Infections Diseases